Nelsen Bio Publishes A New Market Brief On CAR-T

In 2012, the striking clinical success of chimeric antigen receptor T (CAR-T) cell therapy in treating acute lymphoblastic leukemia (ALL) in the case of Emily Whitehead was a real game changer for the industry. Since then, there has been an explosion of commercial activity.

In this CAR-T Deal Review we have captured the number and diversity of deals done in this space over the past four years. Included are strategic partnerships, acquisition and licensing deals done between CAR-T companies, Big Pharma, smaller organizations, and academic institutions from 2012 through August 2016. These deals cover intellectual property, new approaches for creating CARs using gene-editing technologies, expansion to allogeneic approaches, manufacturing, combination therapies, and more.

Collectively these deals are worth at least $2 billion in disclosed upfront payments and $4 billion in additional milestone, royalty and other payments. The number of deals has grown rapidly, from just three in 2012 to 35 in 2015. With already 26 deals as of September 1, 2016, the full-year 2016 numbers will likely reach at least the 2015 total.